In Person

Drug Pricing Transparency Congress

September 27, 2018
Event details
September 27, 2018
7:30 am
Philadelphia, PA

Event summary

State drug pricing regulations remain in the headlines as state legislatures continue to introduce and pass laws aimed at transparency and reporting obligations leaving a myriad of legal and compliance complexities. Over the past year, states including Oregon, California, Nevada, Maryland, New York, Massachusetts and Vermont  have introduced and/or enacted different laws and enforcement initiatives mandating the disclosure of drug pricing increases, introducing restrictions limiting Medicaid drug spending, requiring disclosure of company metrics and expenses, and other related pricing ballot initiatives. Cooley partners Sarah diFrancesca and Vince Sampson will speak at this event.

Topics include:

  • State-by-state analysis – legal update on all pricing and transparency laws passed to date
  • Oregon, California, Nevada and New York transparency laws
  • Practical compliance implications of state pricing and transparency reporting obligations from the first round of July 1, 2018 reports
  • Forecast of future drug pricing policy challenges – what’s ahead for 2019?
  • The potential impact of ICER on drug pricing and rebates

Featured agenda items:  

Implications of State Drug Pricing Transparency Laws on Policy
Hear from state policy and government affairs experts on the following topics:

  • Status of ongoing industry challenges and litigation surrounding state drug pricing laws
  • Unintended consequences of state drug pricing legislation on co-pays, the supply chain and more
  • Medicaid policy developments, copay bans, and patient assistance reporting updates
Cooley partner Vince Sampson is a featured speaker. 

California SB-17 – Implementation and Enforcement Update

California’s SB-17 was implemented in January 2018 – during this spotlight session, our panelist will conduct a deep-dive analysis of the following issues under the law:

  • When are notices issued under SB-17?
  • What information is reported in each of the SB-17 notices?
  • Penalties and considerations
  • Current status of pending industry litigation
Cooley partner Sarah diFrancesca is a featured speaker.

Event details and registration

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.